Disease Synopsis
Overview
Drugs and Clinical Candidates
Clinical Trials (visual)
Clinical Trials (text)
Cell Line Models
Chemistry

Nasal and Sinus Cancer - Overview - Disease Synopsis

Drugs & Clinical Candidates


9 drugs have received FDA approval for Nasal and Sinus Cancer . Arsenic Trioxide, Bosutinib Monohydrate, Dasatinib, Daunorubicin Hydrochloride, Imatinib Mesylate, Midostaurin, Nilotinib Hydrochloride Monohydrate, Thalidomide and Venetoclax
28 drugs have a clinical trial registered for Nasal and Sinus Cancer.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Clinical Trials


There are 52 clinical trials for Nasal and Sinus Cancer,
39 of which have one or more drug interventions,
13 with no drug intervention.

Sources: cancer.gov and clinicaltrials.gov
(see details)

Cell Line Models


There are 0 Cell Line Models for Nasal and Sinus Cancer.

Source: COSMIC
(see details)

Chemistry


There are 3 Compounds which have been tested in Nasal and Sinus Cancer , 3 <= 500nM potency.

Source: ChEMBL
(see details)

Mappings


Please note the mappings below are based on an imperfect algorithm. If you notice any anomalies please report them to us.

The following terms have been mapped from clinicaltrials.gov mesh condition terms to Nasal and Sinus Cancer:
Nose Neoplasms
Paranasal Sinus Neoplasms

The following terms have been mapped from cancer.gov to Nasal and Sinus Cancer:
Acute lymphoblastic leukemia in adults and children that is Philadelphia chromosome positive. In adults, it is used for disease that has recurred (come back) or is refractory (does not respond to treatment). In children, it is used as the first treatment after the disease is diagnosed
Acute myeloid leukemia (AML) that is newly diagnosed. It is used in patients with therapy-related AML (tAML) or AML with myelodysplasia-related changes (AML-MRC)
Acute myeloid leukemia (AML). It is used with cytarabine and daunorubicin hydrochloride in newly diagnosed adults whose cancer has a mutation in the FLT3 gene
Acute myeloid leukemia that is newly diagnosed. It is used in patients aged 75 years and older or adults who cannot be treated with intensive induction chemotherapy. It is given with either azacitidine, decitabine, or low-dose cytarabine
Acute promyelocytic leukemia (APL) in patients whose cancer has a certain type of chromosome mutation that affects the PML gene and RARA gene. It is used:In adults with newly diagnosed APL that is low risk
Chronic myelogenous leukemia (CML) that is Philadelphia chromosome positive. It is used: In adults with newly diagnosed chronic phase CML. This use is approved under FDA??????s Accelerated Approval Program. As a condition of approval, a confirmatory trial(s) must show that bosutinib provides a clinical benefit in these patients
Chronic myelogenous leukemia (CML) that is Philadelphia chromosome positive. It is used:In adults and children aged 1 year or older with newly diagnosed chronic phase CML
In adults with chronic phase CML that is newly diagnosed
Multiple myeloma in patients who have just been diagnosed with the disease